Advanced MRI for Uteroplacental Flow, Perfusion, Oxygenation & Inflammation

Completed

Conditions studied: Pregnancy, Obesity, Preeclampsia

In brief

The purpose of the study is to develop advanced ultrasound (U/S) and Magnetic Resonance Imaging, known as MRI to study uteroplacental health. The goal of this study is to evaluate the blood and oxygen flow to the placenta using advanced U/S and MRI testing.

Key facts

Study ID: NCT02791568
Run by: University of Wisconsin, Madison
People needed: 121
Starts: 2017-01-31
Expected to finish: 2020-07-31
Last updated by the study team: 2025-08-22

Who can join

Age: 18 and older, up to 35. Sex: female. Healthy volunteers: accepted.

You may qualify if…

Women with singleton, low-risk pregnancies
Gravida 1 (first pregnancy); or Gravida 2 (second pregnancy with first pregnancy carried to term or miscarried prior to 14 weeks or terminated); or Gravida 3 (third pregnancy with first and second pregnancies carried to term or one previous pregnancy carried to term and the other previous pregnancy miscarried prior to 14 weeks or terminated)
Ultrasound confirmed pregnancy dating prior to 14 weeks gestation
Non-obese (BMI 18.5-29.9 kg/M2) or Obese (Class I BMI 30-34.9 kg/M2 or Class II BMI 35-39.9 kg/M2) based on pregravid BMI

You may not qualify if…

Known fetal chromosome abnormality, structural malformation or syndromes in current pregnancy
Tobacco or alcohol or drug use in current pregnancy
Pre-existing autoimmune conditions or other maternal chronic diseases like renal diseases, chronic hypertension, thrombophilia, type I or II diabetes or any vasculopathy
History of sickle cell anemia or sickle cell trait
High risk for gestational hypertension, pre-eclampsia, HELLP syndrome, fetal growth restriction (FGR), abruptio placentae secondary to hypertension or pre-eclampsia, stillbirth/intrauterine fetal death
Subject Population (Main study) Inclusion Criteria
Control Group:
Non-obese (pregravid BMI 18.5-29.9 Kg/M2)25 (N=80)
Women with singleton, low-risk pregnancies
Gravida 1 (first pregnancy); or Gravida 2 (second pregnancy with first pregnancy carried to term or miscarried prior to 14 weeks or terminated); or Gravida 3 (third pregnancy with first and second pregnancies carried to term or one previous pregnancy carried to term and the other previous pregnancy miscarried prior to 14 weeks or terminated)
Ultrasound-confirmed pregnancy dating prior to 14 weeks gestation
Gestational age at screening prior to 16 weeks
Study Group:
Obese (pregravid Class I BMI 30-34.9 kg/M2 or pregravid Class II BMI 35-39.9 kg/M2) (N=80)
Women with singleton, low-risk pregnancies
Gravida 1 (first pregnancy); or Gravida 2 (second pregnancy with first pregnancy carried to term or miscarried prior to 14 weeks or terminated); or Gravida 3 (third pregnancy with first and second pregnancies carried to term or one previous pregnancy carried to term and the other previous pregnancy miscarried prior to 14 weeks or terminated)
Ultrasound confirmed pregnancy dating prior to 14 weeks gestation
Gestational age at screening prior to 16 weeks
Exclusion Criteria
Control and Study Groups:
Known fetal chromosome abnormality, structural malformation or syndromes in current pregnancy
Tobacco/alcohol/drug use in current pregnancy
Pre-existing autoimmune conditions or other maternal chronic diseases like renal diseases, chronic hypertension, thrombophilia, type I or II diabetes or any vasculopathy
History of sickle cell anemia or sickle cell trait
High risk for gestational hypertension, pre-eclampsia, HELLP syndrome, fetal growth restriction (FGR), abruptio placentae secondary to hypertension or pre-eclampsia, stillbirth/intrauterine fetal death

Where it is running

UnityPoint Health-Meriter Hospital — Madison, Wisconsin, United States
University of Wisconsin-Hospitals and Clinics — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.